血清补体C1q测定在恶性肿瘤诊断中的意义

王云龙; 李宏森; 吴立翔; 郭变琴; 黄学梅

doi:10.16016/j.2097-0927.202306013

您当前的位置：

首页 >

文章列表页 >

血清补体C1q测定在恶性肿瘤诊断中的意义

临床医学 | 更新时间：2026-01-09

- 血清补体C1q测定在恶性肿瘤诊断中的意义
- Clinical significance of serum complement C1q in diagnosis of malignant tumors
- 陆军军医大学学报 2023年45卷第23期页码：2485-2489
- 作者机构：
  
  1.400030 重庆，重庆大学附属肿瘤医院检验科
  2.650118 昆明，中国医学科学院北京协和医学院医学生物学研究所
- 作者简介：
  
  [黄学梅，E-mail：661203@cqu.edu.cn HUANG Xuemei, E-mail: 661203@cqu.edu.cn
- 基金信息：
- DOI：10.16016/j.2097-0927.202306013
  中图分类号： R446.112;R730.43
- 收稿：2023-06-05，
  
  修回：2023-10-06，
  
  纸质出版：2023-12-15
- 稿件说明：
移动端阅览
王云龙, 李宏森, 吴立翔, 等. 血清补体C1q测定在恶性肿瘤诊断中的意义[J]. 陆军军医大学学报, 2023,45(23):2485-2489.

Yunlong WANG, Hongsen LI, Lixiang WU, et al. Clinical significance of serum complement C1q in diagnosis of malignant tumors[J]. Journal of Army Medical University, 2023, 45(23): 2485-2489.
王云龙, 李宏森, 吴立翔, 等. 血清补体C1q测定在恶性肿瘤诊断中的意义[J]. 陆军军医大学学报, 2023,45(23):2485-2489. DOI： 10.16016/j.2097-0927.202306013.

Yunlong WANG, Hongsen LI, Lixiang WU, et al. Clinical significance of serum complement C1q in diagnosis of malignant tumors[J]. Journal of Army Medical University, 2023, 45(23): 2485-2489. DOI： 10.16016/j.2097-0927.202306013.

摘要

目的

探讨补体C1q在恶性肿瘤患者血清中的水平及其在恶性肿瘤诊断中的临床意义。

方法

血清补体C1q水平采用免疫比浊法进行定量检测，通过LIS系统统计2020年9月至2021年3月在我院初次确诊且未采取任何治疗措施的468例恶性肿瘤患者(其中肺恶性肿瘤患者164例、肝恶性肿瘤患者123例、胃恶性肿瘤患者108例、多发性骨髓瘤患者73例)的血清补体C1q水平进行回顾性分析，同时与健康对照组(50例体检健康者血清C1q水平)进行比较。

结果

肺恶性肿瘤组、肝恶性肿瘤组、胃恶性肿瘤组、多发性骨髓瘤组、健康对照组的血清C1q水平(mg/L)分别为(155.17±34.81)、(164.76±48.79)、(156.87±32.70)、(124.39±31.71)、(191.69±21.94)，与对照组比较，四个恶性肿瘤组的血清C1q水平均显著低于对照组(

0.05)；四组恶性肿瘤患者血清C1q检测的灵敏度均在90%以上，多发性骨髓瘤的诊断效果较好(灵敏度91.7%，特异度86.3%)；以正常组为对照，对多发性骨髓瘤、肺恶性肿瘤、肝恶性肿瘤、胃恶性肿瘤分别作ROC曲线分析，多发性骨髓瘤患者血清补体C1q水平的Cutoff值为157.8 mg/L，AUC面积为0.954；肺恶性肿瘤、肝恶性肿瘤、胃恶性肿瘤、全体肿瘤的补体C1q水平的Cutoff值分别为164.3、164.4、164.3、164.4mg/L，AUC面积分别为0.836、0.757、0.817、0.830。

结论

血清C1q水平测定对恶性肿瘤具有辅助诊断意义，尤其对多发性骨髓瘤的诊断效果较佳。

Abstract

Objective

To investigate the serum level of complement C1q in patients with malignant tumors and its clinical significance in the diagnosis of the tumors.

Methods

A retrospective analysis was conducted on 468 patients with malignant tumors (including 164 cases of lung malignant tumors

123 cases of liver malignant tumors

108 cases of gastric malignant tumors

and 73 cases of multiple myeloma) who were newly diagnosed and had not received any treatment measures from September 2020 to March 2021 in our hospital. Another 50 healthy individuals who taking physical examinations were subjected as control group. The serum level of complement C1q was quantitatively detected using the immunoturbidimetric assay. The levels were compared between the control and the patient groups.

Results

The serum C1q level was 155.17±34.81

164.76±48.79

156.87±32.70 and 124.39±31.71 mg/L

respectively in the lung

liver and gastric malignant tumor groups and multiple myeloma group

and the levels were significantly lower than that of the healthy control group (191.69±21.94 mg/L

0.05). The sensitivity of serum C1q detection in the 4 malignant tumor groups was all above 90%

and the diagnostic efficacy of multiple myeloma was better (sensitivity 91.7%

specificity 86.3%). Using the normal group as a control

ROC curve analysis indicated that the cut-off value of serum complement C1q level in multiple myeloma patients was 157.8 mg/L

with an AUC area of 0.954; and the value was 164.3

164.4

164.3 and 164.4 mg/L for c lung

liver and gastric malignant tumors and all these tumors

respectively

with an AUC value of 0.836

0.757

0.817 and 0.830

respectively.

Conclusion

Serum C1q level determination has auxiliary diagnostic significance for malignant tumors

especially for the diagnosis of multiple myeloma.

关键词

Keywords

references

HUANG H J, TAN M L, ZHENG L, et al . Prognostic implications of the complement protein C1Q and its correlation with immune infiltrates in osteosarcoma[J ] . Onco Targets Ther, 2021, 14: 1737-1751. DOI: 10.2147/OTT.S295063.

朱清红, 张吉才, 康敏. 生物标志物联合检测在早期糖尿病肾病诊断中的应用[J]. 检验医学与临床, 2020, 17(2): 178-182. DOI: 10.3969/j.issn.1672-9455.2020.02.010

ZHU Q H, ZHANG J C, KANG M. Application of combined detection of biomarkers in diagnosis of early diabetic nephropathy[J]. Lab Med Clin, 2020, 17(2): 178-182. DOI: 10.3969/j.issn.1672-9455.2020.02.010

林文婷, 曾敏, 陈积雄, 等. 血清C1q、CTRP1与冠状动脉粥样硬化性心脏病的相关性研究[J]. 中国循证心血管医学杂志, 2019, 11(5): 534-536, 540. DOI: 10.3969/j.issn.1674-4055.2019.05.06

LIN W T, ZENG M, CHEN J X, et al . Correlation between serum C1q, CTRP1 and coronary atherosclerotic heart disease[J ] . Chin J Evid Bases Cardiovasc Med, 2019, 11(5): 534-536, 540. DOI: 10.3969/j.issn.1674-4055.2019.05.06

党晶艺, 郝启萌, 冯品, 等. 血清Gal-3、C1q水平与冠心病的相关性分析[J]. 疑难病杂志, 2019, 18(5): 433-436. DOI: 10.3969/j.issn.1671-6450.2019.05.001

DANG J Y, HAO Q M, FENG P, et al . Analysis of the correlation between serum Gal-3 and C1q levels and coronary heart disease[J ] . Chin J Difficult Complicat Cases, 2019, 18(5): 433-436. DOI: 10.3969/j.issn.1671-6450.2019.05.001

THIELENS N M, TEDESCO F, BOHLSON S S, et al . C1q: A fresh look upon an old molecule[J ] . Molecular Immunology, 2017: 73. doi:10.1016/j.molimm.2017.05.025

BU X M, ZHENG Z Y, WANG C, et al . Significance of C4d deposition in the follicular lymphoma and MALT lymphoma and their relationship with follicular dendritic cells[J ] . Pathol Res Pract, 2007, 203(3): 163-167. DOI: 10.1016/j.prp.2006.11.004.

GASQUE P, THOMAS A, FONTAINE M, et al . Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins[J ] . J Neuroimmunol, 1996, 66(1/2): 29-40. DOI: 10.1016/0165-5728(96)00015-X.

LUCAS S D, KARLSSON-PARRA A, NILSSON B, et al . Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma[J ] . Hum Pathol, 1996, 27(12): 1329-1335. DOI: 10.1016/S0046-8177(96)90346-9.

NICULESCU F, RUS H G, RETEGAN M, et al . Persistent complement activation on tumor cells in breast cancer[J ] . Am J Pathol, 1992, 140(5): 1039-1043.

DOWNS-CANNER S, MAGGE D, RAVINDRANATHAN R, et al . Complement inhibition: a novel form of immunotherapy for colon cancer[J ] . Ann Surg Oncol, 2016, 23(2): 655-662. DOI: 10.1245/s10434-015-4778-7.

杨融辉. 补体C1q在多发性骨髓瘤临床诊治中的意义及机制探讨[D]. 沈阳: 中国医科大学.

YANG R H. Significance and mechanism of complement C1q in clinical diagnosis and treatment of multiple myeloma[D]. Shenyang: China Medical University, .

BULLA R, TRIPODO C, RAMI D, et al . C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation[J ] . Nat Commun, 2016, 7(1): 1-11. DOI: 10.1038/ncomms10346.

AGOSTINIS C, VIDERGAR R, BELMONTE B, et al . Complement protein C1q binds to hyaluronic acid in the malignant pleural mesothelioma microenvironment and promotes tumor growth[J ] . Front Immunol, 2017, doi: 10.3389/fimmu.2017.01559.

HONG Q Y, SZE C I, LIN S R, et al . Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells[J ] . PLoS One, 2009, 4(6): e5755. DOI: 10.1371/journal.pone.0005755.

KAUR A, SULTAN S H A, MURUGAIAH V, et al . Human C1q induces apoptosis in an ovarian cancer cell line via tumor necrosis factor pathway[J ] . Front Immunol, 2016, doi: 10.3389/fimmu.2016.00599.

BANDINI S, MACAGNO M, HYSI A, et al . The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis[J ] . Oncoimmunology, 2016, 5: e1253653. doi: 10.1080/2162402X.2016.1253653.

MANGOGNA A, AGOSTINIS C, BONAZZA D, et al . Is the complement protein C1q a pro- or anti-tumorigenic factor? bioinformatics analysis involving human carcinomas[J ] . Front Immunol, 2019.doi: 10.3389/fimmu.2019.00865.

LEE J H, POUDEL B, KI H H, et al . Complement C1q stimulates the progression of hepatocellular tumor through the activation of discoidin domain receptor 1[J ] . Sci Rep, 2018, 8(1): 1-11. DOI: 10.1038/s41598-018-23240-6.

YANG R H, HUANG J, MA H X, et al . Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma? [J ] . Leukemia & Lymphoma, 2019, doi:10.1080/10428194.2018.1543883.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

经纤维支气管镜射频治疗在恶性中央气道狭窄中的应用

恶性肿瘤儿童社会生活能力调查研究

血清PA测定在恶性肿瘤诊断中的价值及其在手术治疗中的动态观察

小儿食管平滑肌肉瘤1例

恶性肿瘤患者T细胞亚群变化及其与肿瘤分期的关系